Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian G Hartinger

Showing results (111-120 of 190) with videos related to

Pageof 19
Sort By:
Chemical Science|June 2, 2025
X-ray fluorescence microscopy and X-ray absorption spectroscopy reveal the stability of the plecstatin-1 scaffold in biological model systems: comparison of Ru, Os and Ir analoguesJames H Lovett, Barry P Lai, Hugh O Bloomfield, et al.
Journal of Medicinal Chemistry|April 15, 2005
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potentialMichael A Jakupec, Erwin Reisner, Anna Eichinger, et al.
Angewandte Chemie (International Ed. in English)|July 1, 2021
Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct FormationMatthew P Sullivan, Monika Cziferszky, Iogann Tolbatov, et al.
Inorganic Chemistry|January 26, 2021
Mustards-Derived Terpyridine-Platinum Complexes as Anticancer Agents: DNA Alkylation vs CoordinationMuneebah Adams, Matthew P Sullivan, Kelvin K H Tong, et al.
Chemical Communications (Cambridge, England)|May 2, 2018
Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adductMatthew P Sullivan, Michél K Nieuwoudt, Graham A Bowmaker, et al.
Chemical Communications (Cambridge, England)|January 3, 2019
Correction: Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adductMatthew P Sullivan, Michél K Nieuwoudt, Graham A Bowmaker, et al.
Chemical Science|August 18, 2023
Exploiting reduced-symmetry ligands with pyridyl and imidazole donors to construct a second-generation stimuli-responsive heterobimetallic [PdPtL<sub>4</sub>]<sup>4+</sup> cageAston C Pearcy, Lynn S Lisboa, Dan Preston, et al.
Dalton Transactions (Cambridge, England : 2003)|July 6, 2010
Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differencesMuhammad Hanif, Alexey A Nazarov, Christian G Hartinger, et al.
Monatshefte Fur Chemie|September 22, 2018
Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC-ICP-MSMatthias H M Klose, Anna Schöberl, Petra Heffeter, et al.
Journal of Inorganic Biochemistry|December 11, 2025
Additional functionality for plecstatin-1-analogous anticancer Ru(η<sup>6</sup>-p-cymene)Cl complexesShahid Iqbal, Adnan Ashraf, Anne Dill, et al.
Pageof 19

Showing results (111-120 of 190) with videos related to

Sort By:
Pageof 19
Chemical Science|June 2, 2025
X-ray fluorescence microscopy and X-ray absorption spectroscopy reveal the stability of the plecstatin-1 scaffold in biological model systems: comparison of Ru, Os and Ir analoguesJames H Lovett, Barry P Lai, Hugh O Bloomfield, et al.
Journal of Medicinal Chemistry|April 15, 2005
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potentialMichael A Jakupec, Erwin Reisner, Anna Eichinger, et al.
Angewandte Chemie (International Ed. in English)|July 1, 2021
Probing the Paradigm of Promiscuity for N-Heterocyclic Carbene Complexes and their Protein Adduct FormationMatthew P Sullivan, Monika Cziferszky, Iogann Tolbatov, et al.
Inorganic Chemistry|January 26, 2021
Mustards-Derived Terpyridine-Platinum Complexes as Anticancer Agents: DNA Alkylation vs CoordinationMuneebah Adams, Matthew P Sullivan, Kelvin K H Tong, et al.
Chemical Communications (Cambridge, England)|May 2, 2018
Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adductMatthew P Sullivan, Michél K Nieuwoudt, Graham A Bowmaker, et al.
Chemical Communications (Cambridge, England)|January 3, 2019
Correction: Unexpected arene ligand exchange results in the oxidation of an organoruthenium anticancer agent: the first X-ray structure of a protein-Ru(carbene) adductMatthew P Sullivan, Michél K Nieuwoudt, Graham A Bowmaker, et al.
Chemical Science|August 18, 2023
Exploiting reduced-symmetry ligands with pyridyl and imidazole donors to construct a second-generation stimuli-responsive heterobimetallic [PdPtL<sub>4</sub>]<sup>4+</sup> cageAston C Pearcy, Lynn S Lisboa, Dan Preston, et al.
Dalton Transactions (Cambridge, England : 2003)|July 6, 2010
Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differencesMuhammad Hanif, Alexey A Nazarov, Christian G Hartinger, et al.
Monatshefte Fur Chemie|September 22, 2018
Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC-ICP-MSMatthias H M Klose, Anna Schöberl, Petra Heffeter, et al.
Journal of Inorganic Biochemistry|December 11, 2025
Additional functionality for plecstatin-1-analogous anticancer Ru(η<sup>6</sup>-p-cymene)Cl complexesShahid Iqbal, Adnan Ashraf, Anne Dill, et al.
Pageof 19